ARTICLE | Company News
Nerviano, Oxford BioTherapeutics deal
April 18, 2016 7:00 AM UTC
Nerviano granted Oxford BioTherapeutics exclusive rights to use Nerviano’s drug-linker technology against one undisclosed Oxford target for the development of antibody-drug conjugates (ADCs). Oxford, ...